InflaRx N.V (IF0) - Total Assets
Based on the latest financial reports, InflaRx N.V (IF0) holds total assets worth €65.16 Million EUR (≈ $76.18 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See IF0 book value for net asset value and shareholders' equity analysis.
InflaRx N.V - Total Assets Trend (2016–2024)
This chart illustrates how InflaRx N.V's total assets have evolved over time, based on quarterly financial data.
InflaRx N.V - Asset Composition Analysis
Current Asset Composition (December 2024)
InflaRx N.V's total assets of €65.16 Million consist of 94.3% current assets and 5.7% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 24.2% |
| Accounts Receivable | €0.00 | 0.0% |
| Inventory | €6.90 Million | 9.1% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €50.78K | 0.1% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how InflaRx N.V's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see IF0 company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: InflaRx N.V's current assets represent 94.3% of total assets in 2024, a decrease from 99.5% in 2016.
- Cash Position: Cash and equivalents constituted 24.2% of total assets in 2024, down from 98.6% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is inventory at 9.1% of total assets.
InflaRx N.V Competitors by Total Assets
Key competitors of InflaRx N.V based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Royalty Pharma Plc
NASDAQ:RPRX
|
USA | $19.62 Billion |
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $1.30 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥38.02 Billion |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $1.48 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
|
China | CN¥1.84 Billion |
InflaRx N.V - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.33 | 5.31 | 8.54 |
| Quick Ratio | 3.06 | 4.61 | 8.54 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €44.41 Million | €59.75 Million | €76.19 Million |
InflaRx N.V - Advanced Valuation Insights
This section examines the relationship between InflaRx N.V's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.07 |
| Latest Market Cap to Assets Ratio | 0.66 |
| Asset Growth Rate (YoY) | -36.8% |
| Total Assets | €76.02 Million |
| Market Capitalization | $50.33 Million USD |
Valuation Analysis
Below Book Valuation: The market values InflaRx N.V's assets below their book value (0.66x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: InflaRx N.V's assets decreased by 36.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for InflaRx N.V (2016–2024)
The table below shows the annual total assets of InflaRx N.V from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €76.02 Million ≈ $88.87 Million |
-36.76% |
| 2023-12-31 | €120.21 Million ≈ $140.54 Million |
+17.39% |
| 2022-12-31 | €102.40 Million ≈ $119.72 Million |
-18.17% |
| 2021-12-31 | €125.14 Million ≈ $146.30 Million |
+41.86% |
| 2020-12-31 | €88.22 Million ≈ $103.13 Million |
-27.44% |
| 2019-12-31 | €121.58 Million ≈ $142.14 Million |
-23.64% |
| 2018-12-31 | €159.21 Million ≈ $186.14 Million |
+28.18% |
| 2017-12-31 | €124.21 Million ≈ $145.22 Million |
+320.80% |
| 2016-12-31 | €29.52 Million ≈ $34.51 Million |
-- |
About InflaRx N.V
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal … Read more